Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

<p>Baseline tumor H-score levels for AXL positivity by best confirmed overall response per investigator assessment in expansion cohorts. (A) Cohort 3 (Q3W): melanoma with BRAF V600 mutation; (B) cohort 4 (Q3W): melanoma with BRAF V600 wild-type; (C) cohort 5 (Q3W): sarcoma; (D) cohort 6 (3Q4W)...

Fuld beskrivelse

Saved in:
Bibliografiske detaljer
Hovedforfatter: Kristoffer Staal Rohrberg (15009138) (author)
Andre forfattere: Juanita S. Lopez (22687839) (author), Mohammed M. Milhem (15352499) (author), Christian U. Blank (14850778) (author), Irene Reijers (22687842) (author), Fiona Thistlethwaite (22687845) (author), Ruth Plummer (15028641) (author), Sarina A. Piha-Paul (15294428) (author), Pasi A. Jänne (14954872) (author), Elaine Shum (14955138) (author), Heather M. Shaw (22687848) (author), Philip R. Debruyne (20432881) (author), Cristopher Lao (22687851) (author), Jean-Francois Baurain (15031089) (author), Jennifer H. Choe (15052775) (author), Eelke Gort (17740951) (author), Yujie Zhao (22687854) (author), Guy Jerusalem (15017648) (author), Patrick Schöffski (15013461) (author), Andrew William Chen (22687857) (author), Eric A. Cohen (15017996) (author), Walter C. Mankowski (22687860) (author), Leonid Roshkovan (22687863) (author), Sharyn I. Katz (22687866) (author), Despina Kontos (15018005) (author), Lauren K. Brady (22687869) (author), Mohammed Qutaish (22687872) (author), Patricia Garrido Castro (22687875) (author), Nora Pencheva (22687878) (author), Gaurav Bajaj (22687881) (author), Yali Fu (22687884) (author), Kristian Windfeld (22687887) (author), Panagiota Reiter (22687890) (author), Maria Jure-Kunkel (15117740) (author), Brandon W. Higgs (15035279) (author), Katayoun I. Amiri (22687893) (author), Tahamtan Ahmadi (22687896) (author), Ulf Forssmann (22687899) (author), Suresh S. Ramalingam (14951413) (author), Ignace Vergote (15027870) (author)
Udgivet: 2025
Fag:
Cancer
Immuno-oncology
Clinical Research and Trials
Clinical Trial Results
Immunology
Antibodies/immunoconjugates
Lung Cancer
Melanoma
Ovarian Cancer
Sarcomas
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
Beskrivelse
Summary:<p>Baseline tumor H-score levels for AXL positivity by best confirmed overall response per investigator assessment in expansion cohorts. (A) Cohort 3 (Q3W): melanoma with BRAF V600 mutation; (B) cohort 4 (Q3W): melanoma with BRAF V600 wild-type; (C) cohort 5 (Q3W): sarcoma; (D) cohort 6 (3Q4W): other metastatic solid tumors; and (E) cohort 7 (Q3W): platinum-resistant ovarian cancer . CR, complete response; PD, progressive disease; PR, partial response; Q3W, once every 3 weeks; 3Q4W, 3 weekly doses every 4 weeks; SD, stable disease</p>

Lignende værker